(R)-tert-butyl (1-(1,3-dioxoindolm-2-yl)-3,3-dimethylbutan-2-yl)carbamate | 1260589-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (R)-tert-butyl (1-(1,3-dioxoindolm-2-yl)-3,3-dimethylbutan-2-yl)carbamate
• 英文别名: Tert-butyl N-[(2R)-1-(1,3-dioxoisoindol-2-YL)-3,3-dimethylbutan-2-YL]carbamate；tert-butyl N-[(2R)-1-(1,3-dioxoisoindol-2-yl)-3,3-dimethylbutan-2-yl]carbamate
• CAS: 1260589-60-3
• 化学式: C₁₉H₂₆N₂O₄
• 分子量: 346.426
• InChiKey: FFLNGFJKSGHOPH-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl (1-(1,3-dioxoindolm-2-yl)-3,3-dimethylbutan-2-yl)carbamate 在 一水合肼 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Asymmetric Multicomponent Sulfa-Michael/Mannich Cascade Reaction: Synthetic Access to 1,2-Diamino-3-Organosulfur Compounds and 2-Nitro Allylic Amines

  摘要：

  A novel catalytic asymmetric three-component intermolecular sulfa-Michael/Mannich cascade reaction has been developed using a chiral multifunctional catalyst. This reaction provides facile access to 1-amino-2-nitro-3-organosulfur compounds bearing three consecutive stereocenters in high yields (up to 96%) with good diastereo- (up to 91:4:4:1 dr) and excellent enantioselectivities (93-99% ee). Furthermore, the products of this reaction could be facilely transformed into potentially bioactive 1, 2-diamino-3-organosulfur compounds and 2-nitro allylic amines.

  DOI：

  10.1021/acs.orglett.5b02423
• 作为产物：
  描述：

  在 乙酸酐 、 三乙胺 作用下， 生成 (R)-tert-butyl (1-(1,3-dioxoindolm-2-yl)-3,3-dimethylbutan-2-yl)carbamate
  参考文献：
  名称：

  P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile

  摘要：

  SAR studies on the extension of P3 unit of Boceprevir (1, SCH 503034) with amides and lactams and their synthesis is described. Extensive SAR studies resulted in the identification of 36 bearing 4, 4-dimethyl lactam as the new P4 cap unit with improved potency (K-i* 15 nM, EC 90 = 70 nM) and pharmacokinetic properties (Rat AUC (PO) = 3.52 mu M h) compared to 1. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.094

文献信息

• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592A1

  公开（公告）日：2013-05-08

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl g roup, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R4 and R5 e ach independently represent a hydrogen atom; and R2 and R4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种化合物和药物组合物，其具有优异的抑制 Syk 的活性。本发明提供了一种烟酰胺衍生物，由以下式（I）表示 其中 R1 代表卤素原子；R2 代表 C1-12 烷基、C2-12 烯基、C2-12 炔基、C3-8 环烷基、芳基、ar-C1-6 烷基或杂环基，每个基团可选择具有至少一个取代基；R3 代表芳基或杂环基，每个基团可选择具有至少一个取代基；以及 R4 和 R5 分别独立地代表一个氢原子；R2 和 R4 可与它们结合的氮原子一起形成一个环状氨基，该氨基可选择具有至少一个取代基）或其盐，以及一种用于治疗 Syk 相关疾病的药物组合物，该药物组合物包含烟酰胺衍生物或其盐。
• Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus
  申请人：Chen X. Kevin

  公开号：US20070093430A1

  公开（公告）日：2007-04-26

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
• US7173057B2
  申请人：——

  公开号：US7173057B2

  公开（公告）日：2007-02-06
• US7619094B2
  申请人：——

  公开号：US7619094B2

  公开（公告）日：2009-11-17